Lista de obras -

24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids

artículo científico publicado en 2012

Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

artículo científico publicado en 2014

Corrigendum to “Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial” [Res Med 108 (2014) 41–49]

article

Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial

article

Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial

article

Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial

artículo científico publicado en 2013

Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial

artículo científico publicado en 2014

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial

artículo científico publicado en 2011

Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial

artículo científico

Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial

artículo científico publicado en 2014

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

artículo científico publicado en 2011

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

artículo científico

Lung function defects in treated pulmonary tuberculosis patients

artículo científico publicado en 2016

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone ⬇️

artículo científico publicado en 2013

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma

artículo científico publicado en 2013

Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids

artículo científico publicado en 2012

Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Severe Eosinophilic Asthma Patients

article

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial

artículo científico publicado en 2017

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial

artículo científico publicado en 2013

Tuberculosis associates with both airflow obstruction and low lung function: BOLD results

artículo científico publicado en 2015

Lista de obras de

24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids

Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

Corrigendum to “Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial” [Res Med 108 (2014) 41–49]

Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial

Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: A 24-week placebo and active-controlled randomised trial

Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial

Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial

Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial

Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial

Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Lung function defects in treated pulmonary tuberculosis patients

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone ⬇️

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma

Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids

Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Severe Eosinophilic Asthma Patients

Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial

Tuberculosis associates with both airflow obstruction and low lung function: BOLD results